Strategy

January 2021

Pharma UK: The Transdermal Technology – Compact Case

By Julian Birkinshaw

Pharma UK was the UK subsidiary of Pharma, a major international pharmaceuticals company with expertise in oncology, hormone replacement drugs and fertility. Pharma UK was responsible for selling drugs in the local marketplace. However, it…

January 2021

Building an Agile Organisation at ING Bank Netherlands – Compact Case

By Julian Birkinshaw, Ken Mark

ING Group was established through a merger of three Dutch financial services firms in 1991. It expanded internationally into Europe and the Americas, and created a no-frills savings account business called ING Direct in the…

January 2021

Costa Coffee: Project Marlow – Compact Case

By Julian Birkinshaw, Ken Mark

For Jim Slater, head of Costa Express in 2014, the biggest new growth opportunity was to roll out the company’s third-generation vending machine, called Marlow. The product had been developed in record time, but…

October 2020

COVID-19: Pret a Manger’s Fight for Survival

By Nader Tavassoli, Jessica Spungin

The case describes how Pret a Manger—a London casual-dining institution—was significantly adversely impacted by the COVID-19 pandemic, and how they tried to pivot by launching several business experiments in fast succession. The long-term outcome of…

October 2020

Takeda: The governance of strategic transformation (B) (Japanese)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to…

October 2020

Takeda: The Governance of Strategic Transformation (A) (Japanese)

By Harry Korine, Kazuhiro Asakawa

The case series describes strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry doyen has narrowed its strategic focus from six to…

September 2018

David Pyott: The Battle for Allergan (B)

By Randall Peterson, Lisa Duke

This case series charts the evolution of the hostile battle for Allergan and its ultimate sale to a white knight, Actavis. David Pyott had been the CEO of Allergan since January 1998; only the third…

July 2020

Haier’s (2019) ecosystem revolution: From Rendanheyi 2.0 to Rendanheyi 3.0

By Michael Jacobides, Lisa Duke

2019 was an important year for Haier. Its new version of its radically decentralised structure, dubbed Rendanheyi 2.0, based on many independent ‘Ecosystem Micro-enterprise Communities’ (EMCs) had been devised to help it respond to the…

July 2020

Haier’s Rendanheyi 2.0: An ecosystem revolution

By Michael Jacobides, Lisa Duke

Haier in 1984 was a small, local firm on the verge of collapse, with poor-quality products and low morale. Within 30 years, it was transformed by Zhang Ruimin, who took over as CEO, into one…

July 2020

Haier in 2014: An entrepreneurial juggernaut facing a world of platforms and ecosystems

By Michael Jacobides, Lisa Duke

Until the 2010s, China had been known for inexpensive products and efficient, low-cost production and for copycat or OEM products rather than for leading-edge innovation. Yet, in a few short years, Chinese firms turned to…